← All trials
NCT05104216
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Jun 30, 2022
- First posted
- Nov 2, 2021
- Last posted
- Nov 2, 2021
- Enrollment
- 400
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- China National Biotec Group Co., LtdLead sponsor
- Government of ChinaOverall official - principal investigator
- Government of ChinaCollaborator
- Beijing Tiantan Bio Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.